Erratum: Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. (American Society for Biochemistry and Molecular Biology Inc. (2014) 289 (26417-26429) DOI: 10.1074/jbc.M114.553818);Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

Journal of Biological Chemistry

Volumn 289, Issue 38, 2014, Pages 26417-26429

  Dalal, Kush ^a   Roshan Moniri, Mani ^a   Sharma, Aishwariya ^a   Li, Huifang ^a   Ban, Fuqiang ^a   Hessein, Mohamed ^a   Hsing, Michael ^a   Singh, Kriti ^a   LeBlanc, Eric ^b   Dehm, Scott ^a   Tomlinson Guns, Emma S ^a   Cherkasov, Artem ^a   Rennie, Paul S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEXATION; UROLOGY;

ANDROGEN RECEPTORS; DNA-BINDING DOMAIN; IN-VITRO; MECHANISM OF ACTION; PROSTATE CANCERS; RECURRENT PROSTATE CANCERS; TRANSCRIPTIONAL ACTIVITY;

DISEASES;

ANDROGEN RECEPTOR; ENZALUTAMIDE; 4-(4-(4,5-BROMO-1H-IMIDAZOL-1-YL)THIAZOL-2-YL)MORPHOLINE; ANDROGEN RECEPTOR ANTAGONIST; CHROMATIN; IMIDAZOLE DERIVATIVE; ISOPROTEIN; PROTEIN BINDING; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELLULAR DISTRIBUTION; CHROMATIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DRUG BINDING SITE; DRUG DESIGN; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; POINT MUTATION; PROSPECTIVE STUDY; PROSTATE CANCER; RECEPTOR BLOCKING; RNA SPLICING; TRANSCRIPTION REGULATION; TUMOR VOLUME; TUMOR XENOGRAFT; ACTIVE TRANSPORT; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CELL NUCLEUS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSCRIPTION; MCF 7 CELL LINE; METABOLISM; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; TRANSCRIPTION INITIATION;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SEQUENCE; ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; BINDING SITES; CELL NUCLEUS; CHROMATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MALE; MCF-7 CELLS; MICE, NUDE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; THIAZOLES; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907222763     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.A117.553818     Document Type: Erratum

References (48)

1. Green, S. M., and Mostaghel., E. A., and Nelson, P. S. (2012) Androgen action and metabolism in prostate cancer. Mol. Cell. Endocrinol. 360, 3-13
2. Lallous, N., Dalal, K., Cherkasov, A., and Rennie, P. S. (2013) Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int. J. Mol. Sci. 14, 12496-12519
3. Cutress, M. L., and Whitaker., H. C., Mills, I. G., Stewart, M., and Neal, D. E. (2008) Structural basis for the nuclear import of the human androgen receptor. J. Cell Sci. 121, 957-968
4. Lamont, K. R., and Tindall, D. J. (2010) Androgen regulation of gene expression. Adv. Cancer Res. 107, 137-162
5. Saad, F., and Miller, K. (2014) Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens. Urol. Oncol. 32, 70-79
6. Jenster, G., van der Korput, H. A., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., and Brinkmann, A. O. (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 5, 1396-1404
7. Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., and Dalton, J. T. (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 6201-6206
8. Salvati, M. E., Balog, A., Wei, D. D., Pickering, D., Attar, R. M., Geng, J., Rizzo, C.A., and Hunt., J. T., Gottardis, M. M., Weinmann, R., and Martinez, R. (2005) Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1, 3(2H)-dione nucleus. Bioorg. Med. Chem. Lett. 15, 389-393
9. Duke, C. B., Jones, A., Bohl, C. E., Dalton, J. T., and Miller, D. D. (2011) Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets. J. Med. Chem. 54, 3973-3976
10. Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., and Gewirth, D. T. (2004) Structural basis of androgen receptor binding toselective androgen response elements. Proc. Natl. Acad. Sci. U.S.A. 101, 4758-4763
11. He, B., and Gampe., R. T., Jr., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., and Wilson, E. M. (2004) Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell 16, 425-438
12. Estébanez-Perpiñá, E., Arnold, L. A., Arnold, A. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J.D., Guy, R. K., Webb, P., and Fletterick, R. J. (2007) A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl. Acad. Sci. U.S.A. 104, 16074-16079
13. Lack, N. A., Axerio-Cilies, P., Tavassoli, P., and Han., F. Q., Chan, K. H., Feau, C., LeBlanc, E., and Guns., E. T., Guy, R. K., Rennie, P. S., and Cherkasov, A. (2011) Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J. Med. Chem. 54, 8563-8573
14. Dehm, S. M., and Schmidt., L. J., Heemers, H. V., Vessella, R. L., and Tindall, D. J. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469-5477
15. Hu, R., and Dunn., T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., and Partin., A. W., Vessella, R. L., Isaacs, W. B., Bova, G. S., and Luo, J. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22
16. Guo, Z., Yang, X., Sun, F., Jiang, R., and Linn., D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., Kung, H. J., Brodie, A. M., Edwards, J., and Qiu, Y. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletionresistant growth. Cancer Res. 69, 2305-2313
17. Sun, S., and Sprenger., C. C., Vessella, R. L., Haugk, K., Soriano, K., and Mostaghel., E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., Nelson, P. S., and Plymate, S. R. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730
18. Watson, P.A., Chen, Y. F., and Balbas., M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., and Sawyers, C. L. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl. Acad. Sci. U.S.A. 107, 16759-16765
19. Chan, S. C., Li, Y., and Dehm, S. M. (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J. Biol. Chem. 287, 19736-19749
20. Li, Y., and Chan., S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A., and Dehm, S. M. (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73, 483-489
21. Nyquist, M. D., and Dehm, S. M. (2013) Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Horm. Cancer 4, 61-69
22. Nyquist, M. D., Li, Y., Hwang, T. H., Manlove, L. S., Vessella, R. L., Silverstein, K. A., Voytas, D. F., and Dehm, S. M. (2013) TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 17492-17497
23. Munuganti, R. S., Leblanc, E., Axerio-Cilies, P., Labriere, C., Frewin, K., Singh, K., Hassona, M. D., Lack, N. A., Li, H., Ban, F., Tomlinson Guns, E., Young, R., Rennie, P. S., and Cherkasov, A. (2013) Targeting the binding function3(BF3) site of the androgen receptor through virtual screening. 2. Development of2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives. J. Med. Chem. 56, 1136-1148
24. Li, H., Ren, X., Leblanc, E., Frewin, K., and Rennie., P. S., and Cherkasov, A. (2013) Identification of novel androgen receptor antagonists using structure- and ligand-based methods. J. Chem. Inf. Model. 53, 123-130
25. Li, H., Ban, F., Dalal, K., Leblanc, E., Frewin, K., Ma, D., Adomat, H., and Rennie., P. S., and Cherkasov, A. (2014) Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor. J. Med. Chem. 10.1021/jm500802j
26. Miesfeld, R., Rusconi, S., Godowski, P.J., Maler, B.A., Okret, S., Wikström, A. C., Gustafsson, J. A., and Yamamoto, K. R. (1986) Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell 46, 389-399
27. Klock, H. E., and Koesema., E. J., Knuth, M. W., and Lesley, S. A. (2008) Combining the polymerase incomplete primer extension method for cloning and mutagenesis with microscreening to accelerate structural genomics efforts. Proteins 71, 982-994
28. van Royen, M.E., van Cappellen, W. A., de Vos, C., Houtsmuller, A.B., and Trapman, J. (2012) Stepwise androgen receptor dimerization. J. Cell Sci. 125, 1970-1979
29. Lim, M., Otto-Duessel, M., He, M., Su, L., Nguyen, D., Chin, E., Alliston, T., and Jones, J. O. (2014) Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium. ACS Chem. Biol. 9, 692-702
30. Snoek, R., Bruchovsky, N., Kasper, S., Matusik, R. J., Gleave, M., Sato, N., and Mawji., N. R., and Rennie, P. S. (1998) Differential transactivation by the androgen receptor in prostate cancer cells. Prostate 36, 256-263
31. Bredel, M., and Jacoby, E. (2004) Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. 5, 262-275
32. Nelson, P. S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., and Lin, B. (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. U.S.A. 99, 11890-11895
33. Magee, J. A., and Chang., L. W., Stormo, G. D., and Milbrandt, J. (2006) Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 147, 590-598
34. Ellinger-Ziegelbauer, H., Fostel, J. M., Aruga, C., Bauer, D., Boitier, E., Deng, S., Dickinson, D., Le Fevre, A. C., Fornace, A. J., Jr., Grenet, O., Gu, Y., Hoflack, J. C., Shiiyama, M., Smith, R., Snyder, R. D., Spire, C., Tanaka, G., and Aubrecht, J. (2009) Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms. Toxicol. Sci. 110, 341-352
35. Ferraldeschi, R., Pezaro, C., Karavasilis, V., and de Bono, J. (2013) Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. Annu. Rev. Med. 64, 1-13
36. Rathkopf, D., and Scher, H. I. (2013) Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J. 19, 43-49
37. Miyake, H., Nelson, C., Rennie, P. S., and Gleave, M. E. (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60, 2547-2554
38. Sato, N., and Gleave., M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. H., and Sullivan, L. D. (1996) Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J. Steroid Biochem. Mol. Biol. 58, 139-146
39. Cheng, H., Snoek, R., Ghaidi, F., Cox, M. E., and Rennie, P. S. (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-in-dependent activation and delays tumor progression. Cancer Res. 66, 10613-10620
40. Snoek, R., Cheng, H., Margiotti, K., Wafa, L. A., Wong, C. A., Wong, E. C, Fazli, L., Nelson, C. C, Gleave, M. E., and Rennie, P. S. (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well established, castration-resistant prostate tumors. Clin. Cancer Res. 15, 39-47
41. Kuruma, H., Matsumoto, H., Shiota, M., Bishop, J., Lamoureux, F., Thomas, C, Briere, D., Los, G., Gleave, M., Fanjul, A., and Zoubeidi, A. (2013) A novel antiandrogen, compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol. Cancer Ther. 12, 567-576
42. Zhang, K. X., Moussavi, M., Kim, C., Chow, E., and Chen., I. S., Fazli, L., Jia, W., and Rennie, P. S. (2009) Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells. Cancer Gene Ther. 16, 820-831
43. Caboni, L., and Lloyd, D. G. (2012) Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. Med. Res. Rev. 33, 1081-1118
44. Andersen, R. J., and Mawji., N. R., Wang, J., Wang, G., Haile, S., and Myung., J. K., Watt, K., Tam, T., Yang, Y. C, Bañuelos, C. A., Williams, D. E., McEwan, I. J., Wang, Y., and Sadar, M. D. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17, 535-546
45. Nickols, N. G., and Dervan, P. B. (2007) Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc. Natl. Acad. Sci. U.S.A. 104, 10418-10423
46. Taplin, M. E., and Bubley., G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl. J. Med. 332, 1393-1398
47. Tran, C, Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P.M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., and Sawyers, C. L. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790
48. Thorne, C. A., and Hanson., A. J., Schneider, J., Tahinci, E., Orton, D., and Cselenyi., C. S., Jernigan, K. K., Meyers, K. C, Hang, B. I., Waterson, A. G., Kim, K., Melancon, B., Ghidu, V. P., Sulikowski, G. A., La Fleur, B., Salic, A., Lee, L. A., Miller, D. M., 3rd, and Lee, E. (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat. Chem. Biol. 6, 829-836